Recent Modalities in Management of Gastrointestinal Stromal Tumours

Essay
Submitted for partial fulfillment of master degree in
General Surgery

By

Weam Latif Ayad

M.B., B.Ch Faculty of Medicine Cairo University

Under supervision of

Prof. Dr. Sameh Abd-Allah Maaty

Professor of General Surgery Faculty of Medicine Ain shams University

Dr. Sayed Adel El-Desouky

Lecturer of General Surgery Faculty of Medicine Ain Shams University

Faculty of Medicine Ain Shams University 2014



First of all, I should express my deep thanks to **Allah**, without his great blessing, I would never accomplish my work, and to whom I relate any success in achieving any work in my life.

I would like to express my sincere appreciation and deepest gratitude to **Prof. Dr. Sameh Abd-Allah Maaty** professor of General Surgery, Ain-Shams University, for his meticulous advice, continuous encouragement and valuable instructions, help, all through this work, honest assistance and active guidance and the precious time he had given in follow up of this work.

I am deeply grateful to **Prof. Dr. Hanna Habib Hanna,** assistant professor of General Surgery ,Ain-Shams
University and **Dr. Sayed Adel El-Desouky,** lecturer of
General surgery, Ain Shams University ,of every word and every
step in this work have been kindly arranged by his sincere effort,
care.

My truthful affection and love to My Family, who were and will always be, by my side all my life.

Contents

| List of Abbreviations | i |
|--|-----|
| List of Tables | ii |
| List of Figures | iii |
| Introduction and Aim of the Work | 1 |
| Pathology of GIST | 4 |
| Diagnosis of GIST | 31 |
| Recent modalities in treatment of GIST | 63 |
| Summary | 102 |
| References | 106 |
| Arabic Summary\ | |

. . .

List of Abbreviations

| Abbrev. | Full Term |
|------------------|---|
| AIDS | Aquired immunodeficiency syndrome. |
| BID | Twice daily. |
| СВ | Clinical benefit . |
| CGH | Comparative genomic hybridization. |
| CML | Chronic myeloid leukemia or Chronic myelogenous leukemia. |
| C _{min} | Plasma concentration. |
| CR | Complete response. |
| DFS | Disease free survival. |
| DOG 1 | Discovered on GIST 1. |
| EUS | Endoscopic ultrasonography. |
| GANTs | Gastrointestinal autonomic tumors. |
| GI | Gastrointestinal. |
| GIT | Gastrointestinal tract. |
| GISTs | Gastrointestinal stromal tumors. |
| GIST/Ls | Gastrointestinal stromal tumors and leiomyomas, |
| GIPACTs | Gastrointestinal pacemaker cell tumors. |
| JM | Juxtamembrane. |
| HAE | Hepatic arterial embolization. |
| HPF | High power field. |
| HTERT | Human telomerase reverse transcriptase. |
| HTR | Human telomerase RNA component. |
| ICCs | Interstitial cells of Cajal. |

List of Abbreviations (cont.)

| IM | Imatinib Mesylate. |
|--------|--|
| LMP | Low malignant potential. |
| MVD | Microvessel density. |
| OD | Once daily. |
| OS | Overall survival. |
| PD | Progressive disease. |
| PDGFRα | Platelet-derived growth factor receptor alpha. |
| PFS | Progression-free survival. |
| PR | Partial response. |
| RECIST | Response Evaluation Criteria in Solid Tumors . |
| RR | Response rate. |
| SD | Stable disease. |
| SMemb | Embryonic isoform of myosin heavy chain. |
| SMA | Smooth muscle actin. |
| SU | Sunitinib. |
| SUVmax | Maximum standardized uptake value. |
| TAP1 | Telomerase-associated protein 1. |
| VEGFRs | Vascular endothelial growth factor receptors. |

List of tables

| Table | Title | Page |
|-------|--|------|
| 1 | Risk classification of GISTs according | 23 |
| | to Miettinen,2008. | |
| 2 | Risk classification of GISTs according | 24 |
| | to Joensuu, 2008. | |
| 3 | TNM classifications of GIST. | 25 |

List of Figures

| Fig. | Title | Page |
|------|--|------|
| 1 | Distribution of GIST of GIT. | 10 |
| 2 | Gross appearance of GIST. | 11 |
| 3 | Macroscopic appearance of GIST of | 12 |
| | Ilium. | |
| 4 | Microscopic appearances of GIST | 14 |
| 5 | positive E2F1 immunostaining in | 16 |
| | malignant GIST. | |
| 6 | P27KIP1 expression in LMP GIST. | 18 |
| 7 | P16 immunostaining in LMP GIST. | 19 |
| 8 | DOG1 immunopositivity of GIST. | 21 |
| 9 | Hematoxylin and eosin of malignant | 22 |
| | GIST. | |
| 10 | Gastric GIST arises from the lesser | 34 |
| | curvature. | |
| 11 | Gastric GIST arises from greater | 34 |
| | curveature. | |
| 12 | large exophytic gastric GIST arises from | 36 |
| | the greater curve by Ultasound. | |
| 13 | Barium meal shows gastric GIST. | 37 |
| 14 | CT shows gastric GIST. | 38 |
| 15 | CT shows Jejunal GIST. | 39 |
| 16 | CT shows posterior wall gastric GIST. | 40 |
| 17 | CT shows GIST of the stomach with | 42 |
| | liver metastases. | |
| 18 | CT shows benign GIST of gastric body. | 42 |
| 19 | CT shows GIST of the gastric antrum | 43 |
| | and body. | |

List of Figures (Cont.)

| Fig. | Title | Page |
|------|--|------|
| 20 | CT shows duodenal GIST. | 44 |
| 21 | CT shows GIST of gastric fundus. | 45 |
| 22 | CT shows large GIST of the small bowel | 46 |
| | mesentry. | |
| 23 | MRI shows rectal GIST. | 49 |
| 24 | MRI shows GIST of the lesser curve | 50 |
| | stomach. | |
| 25 | Angiography of GIST | 53 |
| 26 | Gastric Gist by EUS | 56 |
| 27 | Left parasagittal view of Transrectal | 56 |
| | sonography showing the anterolateral | |
| | wall of rectum | |
| 28 | Puncture of the small GIST under direct | 59 |
| | endosonographic visualization. | |
| 29 | EUS-FNA smear of GIST(modified | 60 |
| | Giemsa Stain). | |
| 30 | Treatment algorithm for patients who are | 65 |
| | diagnosed with GIST in the Imatinib era. | |
| 31 | Gastric GIST excision. | 69 |
| 32 | Laparscopic excision of GIST of lesser | 73 |
| | curvature of stomach. | |
| 33 | GIST of Antrum of Stomach. | 74 |
| 34 | GIST of Small Intestine. | 76 |
| 35 | GIST of Large intestine. | 76 |
| 36 | Trans rectal approach of rectal GIST. | 77 |

List of Figures (Cont.)

| Fig. | Title | Page |
|------|--------------------------------------|------|
| 37 | Endscopic excision of GIST. | 81 |
| 38 | Chemical structure of Imatinib. | 85 |
| 39 | Development of fluid retention as an | 88 |
| | adverse effect of Imatinib. | |
| 40 | Hepatic artery embolization of GIST. | 97 |
| 41 | Radio requency ablation of liver | 99 |
| | metastasis from GIST. | |

Introduction

Gasrtointestinal stromal tumours(GISTs) are neoplasms that arise from either mesenchymal tissue of gastrointestinal tract or from other intraabdominal soft tissue. They arise from stem cell called interstitial cell of Cajal. (*Corlos et al.*, 2005).

GIST occur any where along gastrointestinal tract most commonly in the stomach and small intestine and less commonly in the colon and rectum. (*Jonsuu*, 2012).

The malignant potential of GIST ranges from small lesions with benign behavior to malignant sarcoma. 40% of GIST tumours that are localized at time of detection give rise to metastasis. (*Emile*,2012).

Although patients have symptoms or a palpable tumour at presentation ,25% of GIST discovered incidently during surgery or imaging for other disorders. The most frequent symptoms are abdominal pain , bleeding in bowel, dyspepsia or vomiting. (*Nilsson et al.*, 2005).

Endoscopic contrast enhanced ultrasound is valuable for assessment of large gastric, duodenal and rectal GISTs, Imaging by CT or MRI is usually needed. (*Jonsuu*, 2012).

Surgery is the mainstay of therapy for a primary non-metastatic GISTs ,but probability of recurrence depends on

Introduction and Aim of The Work

tumor characterestics. Following removal of primary GIST, patients at risk of recurrence need adjuvant therapy with Imatinib. Patients with metastatic GIST, even if removed ,definitely need drug treatment to maintain tumour control. Lymph node metastasis are rare and routine removal of lymph nodes is typically not necessary, also wide margins are not necessary. Laparoscopic surgery has been shown to be effective on removal of these tumors without the need of large incisions. (Nguyen et al., 2006).

The c-kit tyrosine kinase inhibitor Imatinib (Glivec/Gleevec), a drug initially marked for chronic myelogenous leukemia, was found to be useful in treating GISTs, leading to a 40-70% response rate in metastatic or inoperable cases. Patients who become refractory on Imatinib ,may respond to the multiple tyrosin kinase inhibitor sunitinib (Sutent) (*Eisenberg et al.*, 2009).

Introduction and Aim of The Work

Aim of the Work

The aim of this work is to discuss and review the recent modalities in management of gastrointestinal stromal tumours.

Pathology of GIST

GISTs account for 5% of all soft tissue sarcomas, predominantly occur in middle aged and older patients (fifth to seventh decades). The cell of Cajal is the cell of origin of Gist.Gist can be classified into benign,malignant and low malignant according to its site ,size and mitotic activity (Sullivan et al., 2006).

Incidence of Gist:

GISTs account for 5% of all soft tissue sarcomas, predominantly occur in middle aged and older patients (fifth to seventh decades) (*Barnes et al.*, 2005).

Some studies show no significant sex difference, whilst others show a male predominance. Sporadic instances are rare before the age of forty. However, GISTs can be familial, thus can be present in younger patients (*Sullivan et al.*, 2006).

Cells of Origin of Gist "ICCS":

The cells of Cajal are intercalated between the autonomic nerves and the muscle layers of the gastrointestinal tract, functioning as gastrointestinal pacemaker cells that are important for the autonomous intestinal motility (*Anthony et al.*, 2005).

Pathology of GIST

ICCs play important roles, such as the pacemaker that enables cooperative peristalsis or as the mediator of nitric oxide-mediated transmission from nerve terminals to smooth muscle cells in the gastrointestinal tract. Simultaneous expression of specific molecules such as KIT, CD34, the embryonic isoform of myosin heavy chain (SMemb), and nestin in both ICCs and GISTs leads to consider that GISTs may develop from ICCs or their progenitor cells (*Shinji et al.*, 2004).

Multifocal hyperplasia of interstitial cells of Cajal has been described as precursor of hereditary GIST in patients with germline mutations in c-KIT and PDGFRA (*platelet-derived growth-factor receptor, alpha polypeptide*), with GIST tumorlets (microscopic GIST) being the counterpart caused by somatic mutations in c-KIT or PDGFRA in patients with sporadic GIST(*Agaimy et al., 2007*).

Aetiology and Risk Factors of Gist:

Risk factors and aetiology are unknown, but there is a rare association with neurofibromatosis type. Some studies show no significant sex difference, whilst others show a male predominance. Most GISTs occur in older patients, typically between the ages of 50-60. Sporadic instances are rare before